CorMedix Inc. (CRMD)

Market Cap	188.55M
Revenue (ttm)	29,702
Net Income (ttm)	-39.79M
Shares Out	54.81M
EPS (ttm)	-0.86
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	509,751
Open	3.60
Previous Close	3.56
Day's Range	3.50 - 3.63
52-Week Range	2.57 - 6.09
Beta	1.86
Analysts	Strong Buy
Price Target	14.60 (+312.43%)
Earnings Date	Nov 14, 2023

About CRMD

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath and Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly know...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 25, 2010
• Employees: 40
• Stock Exchange: NASDAQ
• Ticker Symbol: CRMD

Financial Performance

In 2022, CorMedix's revenue was $65,408, a decrease of -65.74% compared to the previous year's $190,936. Losses were -$29.70 million, 5.29% more than in 2021.

Analyst Forecast

According to 5 analysts, the average rating for CRMD stock is "Strong Buy." The 12-month stock price forecast is $14.6, which is an increase of 312.43% from the latest price.

Price Target

$14.6

(312.43% upside)

Analyst Consensus: Strong Buy